ARCHIVES

Phase III Cyramza Trial Meets OS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

September 27, 2013

The Cancer Letter Takes Summer Publication Break.

August 2, 2002

NCI Advisory Groups To Be Cut By One-Third

April 22, 1977

Oncology Nurses Urged To Help Set Agenda For Health Care Reform

May 29, 1992

Drugs and Targets: FDA approves Velcade in mantle cell lymphoma

October 17, 2014

Review Of Organ Site Program Requested By NCAB Set For Nov. 23-25; Eight Member Committee Named

August 21, 1981